CD2 and inflammatory bowel disease: These samples correspond to six participants diagnosed as non-IBD (nIBD1 and nIBD2), Crohn’s disease, (CD1 and CD2) and ulcerative colitis, (UC1 and UC2), which were followed for 1 year each (Supplementary Figure S2, Supplementary Table S1).